These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 14657693

  • 1. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate.
    Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN.
    Transplantation; 2003 Nov 27; 76(10):1498-502. PubMed ID: 14657693
    [Abstract] [Full Text] [Related]

  • 2. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
    Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D.
    N Engl J Med; 2004 Feb 19; 350(8):767-76. PubMed ID: 14973216
    [Abstract] [Full Text] [Related]

  • 3. Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover.
    Cohen A, Addesso V, McMahon DJ, Staron RB, Namerow P, Maybaum S, Mancini D, Shane E.
    Transplantation; 2006 Mar 15; 81(5):686-91. PubMed ID: 16534469
    [Abstract] [Full Text] [Related]

  • 4. Alendronate is effective to treat bone loss in renal transplantation recipients.
    Lan G, Peng L, Xie X, Peng F, Wang Y, Yu S.
    Transplant Proc; 2008 Dec 15; 40(10):3496-8. PubMed ID: 19100422
    [Abstract] [Full Text] [Related]

  • 5. Alendronate prevents further bone loss in renal transplant recipients.
    Giannini S, D'Angelo A, Carraro G, Nobile M, Rigotti P, Bonfante L, Marchini F, Zaninotto M, Dalle Carbonare L, Sartori L, Crepaldi G.
    J Bone Miner Res; 2001 Nov 15; 16(11):2111-7. PubMed ID: 11697808
    [Abstract] [Full Text] [Related]

  • 6. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
    J Bone Miner Res; 1998 Sep 15; 13(9):1431-8. PubMed ID: 9738515
    [Abstract] [Full Text] [Related]

  • 7. Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study.
    Marcén R, Caballero C, Pascual J, Teruel JL, Tenorio M, Ocaña J, Villafruela JJ, Burgos FJ, Fernández AM, Muriel A, Ortuño J.
    Transplantation; 2006 Mar 27; 81(6):826-31. PubMed ID: 16570003
    [Abstract] [Full Text] [Related]

  • 8. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research Group.
    J Bone Miner Res; 2004 Aug 27; 19(8):1259-69. PubMed ID: 15231012
    [Abstract] [Full Text] [Related]

  • 9. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May 27; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 10. Prevention of bone loss in paraplegics over 2 years with alendronate.
    Zehnder Y, Risi S, Michel D, Knecht H, Perrelet R, Kraenzlin M, Zäch GA, Lippuner K.
    J Bone Miner Res; 2004 Jul 27; 19(7):1067-74. PubMed ID: 15176988
    [Abstract] [Full Text] [Related]

  • 11. Calcitriol and alendronate combination treatment in menopausal women with low bone mass.
    Malavolta N, Zanardi M, Veronesi M, Ripamonti C, Gnudi S.
    Int J Tissue React; 1999 Jul 27; 21(2):51-9. PubMed ID: 10568224
    [Abstract] [Full Text] [Related]

  • 12. Effect of one-year post-operative alendronate treatment on periprosthetic bone after total knee arthroplasty. A seven-year randomised controlled trial of 26 patients.
    Jaroma AV, Soininvaara TA, Kröger H.
    Bone Joint J; 2015 Mar 27; 97-B(3):337-45. PubMed ID: 25737517
    [Abstract] [Full Text] [Related]

  • 13. Effect of calcitriol on bone loss after cardiac or lung transplantation.
    Sambrook P, Henderson NK, Keogh A, MacDonald P, Glanville A, Spratt P, Bergin P, Ebeling P, Eisman J.
    J Bone Miner Res; 2000 Sep 27; 15(9):1818-24. PubMed ID: 10977001
    [Abstract] [Full Text] [Related]

  • 14. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR, Hamdy NA, Pereira AM, Romijn JA, Roelfsema F.
    Clin Endocrinol (Oxf); 2004 May 27; 60(5):568-75. PubMed ID: 15104559
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.
    Shane E, Cohen A, Stein EM, McMahon DJ, Zhang C, Young P, Pandit K, Staron RB, Verna EC, Brown R, Restaino S, Mancini D.
    J Clin Endocrinol Metab; 2012 Dec 27; 97(12):4481-90. PubMed ID: 23024190
    [Abstract] [Full Text] [Related]

  • 20. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
    Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB.
    J Clin Endocrinol Metab; 2002 Oct 27; 87(10):4528-35. PubMed ID: 12364430
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.